Categories

News

Generation of mitochondrial replacement monkeys by female pronucleus transfer-Chinese Academy of Sciences
2024-11-18
This study created four healthy cynomolgus monkeys using pronuclear transfer, with minimal mtDNA carryover and stable mtDNA dynamics. It highlights the potential of this method for preventing mtDNA diseases and advancing mitochondrial replacement therapies in humans.T(The subsequent HVJ-E cell fusion reagent product procurement from the Chinese Academy of Sciences(Shanghai) has been replaced with Melton's.)
Hemagglutinating Virus of Japan Envelope (HVJ-E)-Guided  Gene Transfer to the Intestinal Epithelium
2024-11-10
The passage introduces intestine-specific gene transfer (iGT), a method for delivering small molecules like siRNAs and plasmids into the intestinal epithelium of living mice using the Hemagglutinating Virus of Japan Envelope (HVJ-E). This technique offers a faster and more efficient alternative to traditional genetic engineering in mice, aiding research on intestinal stem cell-driven tissue renewal and tumorigenesis.
Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)
2024-11-09
"Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study)" is a preliminary study showing that oncolytic Sendai virus (SeV) can inhibit tumor growth in canine mast cell tumors (MCT) by selectively targeting and destroying tumor cells. This research provides early evidence for SeV as a potential cancer therapy and supports future clinical trials.
Dose‑escalation, tolerability, and efficacy of intratumoral  and subcutaneous injection of hemagglutinating virus of Japan  envelope (HVJ‑E) against chemotherapy‑resistant malignant pleural  mesothelioma: a clinical tria
2024-11-02
This phase I study evaluated HVJ-E, an inactivated Sendai virus particle, for safety and preliminary efficacy in chemotherapy-resistant MPM. High doses led to stable disease, while low doses saw progression, indicating a dose-dependent antitumor effect with no serious adverse events. Findings support a phase II trial with higher doses. Trial registration: UMIN000019345.
Product Evaluation - Testing iPSC Reprogramming of Fibroblasts Using MeltonVEC™-Sendai iPSC Reprogramming Kit (Including Experimental Methods)
2024-10-17
This article describes how one of our customers who applied MeltonVEC-Sendai iPSC Reprogramming Kit on the transduction of newborn fibroblasts into iPSCs successfully. There are detailed materials and methodology, highly illustrated results in this informative article.
Notice regarding customer inquiries about technical details and products.
2024-10-14
'Contact Us' inquiry feature has been added at the bottom of the website homepage. You can submit technical and product-related inquiries through this option.
Application of Sendai virus-“Sendai virus-mediated RNA delivery restores fertility to congenital and chemotherapy-induced infertile female mice”
2024-10-07
The article discusses the research on the use of Sendai virus (SeV) for treating congenital and chemotherapy-induced infertility. The study shows that SeV successfully restores fertility in mice by enhancing KITL expression without the risk of viral gene integration. SeV therapy demonstrates potential for protecting fertility and offers new insights for future clinical applications.
MeltonVEC™-Cell Fusion Kit (HVJ): Supplementary description
2024-10-03
Our company produces the "MeltonVEC-Cell Fusion Kit", which operates on the same principle as the "GenomONE-CF EX" product. The cell fusion efficiency exceeds 75%, and the usage method is nearly identical. PBS may be used to resuspend the freeze-dried product.

Contact Us

Technical inquiries and product quotation
FirstName *
LastName
Email *
Message *
Describe the question you would like to inquire about